Stockscreener 앱 받기
15.50
2.15%
-0.34
시간 외 거래:
15.90
0.40
+2.58%
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE) - simplywall.st
Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G - Stock Titan
Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership - Stock Titan
GLUE|Monte Rosa Therapeutics Inc|Price:15.500|Chg%:-0.340 - TradingKey
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21% - webull.com
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update - Sahm
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results - webull.com
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results - MarketBeat
MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29 - webull.com
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance Singapore
The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
JPMorgan Chase & Co. Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - MarketBeat
Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00 - MarketBeat
Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo - Moomoo
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal - Yahoo Finance
Monte Rosa Therapeutics earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
(GLUE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Monte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside - TradingView
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold" - MarketBeat
Monte Rosa Therapeutics: Q2 Earnings Snapshot - AOL.com
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D - TradingView
Monte Rosa posts $43.4 million Q2 loss as pipeline trials advance - Quiver Quantitative
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, Vs. FactSet Est of $12.9M - Moomoo
Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029 - TradingView
Monte Rosa Therapeutics Q2 2026: Revenue $9M, EPS $(0.43) — 10-Q Summary - TradingView
Monte Rosa Therapeutics (NASDAQ: GLUE) posts 2026 net loss on revenue drop - Stock Titan
BRIEF-Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million - TradingView
Press Release: Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Moomoo
Monte Rosa Q2 2026 earnings: Higher R&D widens loss as pipeline advances - TradingKey
Monte Rosa earnings on deck as cardiovascular data looms By Investing.com - Investing.com India
Monte Rosa Eyes Key Pipeline Readouts; Wedbush Analyst Reiterates Outperform Rating - RTTNews
Janus Henderson Group PLC Invests $11.29 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Renaissance Technologies LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $27.00 at Wedbush - MarketBeat
Monte Rosa Therapeutics (GLUE) Plunges 27%: Critical Support Test After Steep SelloffConversion Trade - dars.gov.et
Arrowstreet Capital Limited Partnership Acquires 340,088 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Why is Monte Rosa Therapeutics stock plunging today? By Investing.com - Investing.com Canada
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline - Seeking Alpha
Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday - MarketBeat
Monte Rosa Therapeutics Inc - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Exome Asset Management LLC Takes $2.95 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Inc (GLUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Cash Flow - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Income Statement - TradingKey
Monte Rosa Therapeutics, Inc. Revenue Breakdown – BOATS:GLUE - TradingView
Monte Rosa Therapeutics Inc (GLUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
GLUE|Monte Rosa Therapeutics Inc|Price:22.780|Chg%:-0.250 - TradingKey
Price to sales forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics Market Sentiment - Benzinga España
Price to sales forward of Monte Rosa Therapeutics, Inc. – BOATS:GLUE - TradingView
Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - The Manila Times
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Have Insiders Sold Monte Rosa Therapeutics Shares Recently? - simplywall.st
Enterprise value to revenue forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Price to earnings forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
0.52%
0.07%
자본화:
|
볼륨(24시간):